THTX Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (25 Apr 2024 @ 12:52):

Stats
Today's Volume	19 949.00
Average Volume	36 017.00
Market Cap	60.46M
EPS	$0 ( 2024-04-10 )
Next earnings date	( $-0.0300 ) 2024-07-10
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-1.450
ATR14	$0.0140 (1.06%)

Theratechnologies Inc Correlation

10 Most Positive Correlations
AVO	0.931
XFOR	0.927
FATE	0.923
QTEK	0.922
IMCC	0.92
BVXV	0.915
ALZN	0.913
AMTI	0.911
GOSS	0.911
RDHL	0.911

10 Most Negative Correlations
DVCR	-0.985
OPNT	-0.973
EWEB	-0.961
LMNX	-0.954
EDUT	-0.95
AVEO	-0.948
CIH	-0.939
ITMR	-0.934
BKCH	-0.932
HZNP	-0.929

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Theratechnologies Inc Financials

Annual	2023
Revenue:	$81.76M
Gross Profit:	$62.13M (75.99 %)
EPS:	$-0.910

Q1	2024
Revenue:	$16.09M
Gross Profit:	$10.34M (64.29 %)
EPS:	$-0.0965

Q4	2023
Revenue:	$23.45M
Gross Profit:	$18.39M (78.40 %)
EPS:	$-0.0800

Q3	2023
Revenue:	$20.86M
Gross Profit:	$15.89M (76.18 %)
EPS:	$-0.0308

Financial Reports:

No articles found.

Theratechnologies Inc

Theratechnologies Inc., a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA and EGRIFTA SV, for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo, an injection refers to ibalizumab for the treatment of multidrug resistant HIV-1 infected patients. Its pipeline products include F8 Formulation for the treatment of lipodystrophy in people living with HIV; TH1902, which is in Phase 1/Part A clinical trials for the treatment of triple negative breast cancer; and TH1904 for the treatment of ovarian cancer. The company was incorporated in 1993 and is headquartered in Montreal, Canada.